Clinical trial
Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell…
NCT00151320 · Weill Medical College of Cornell University, Other · Completed
Key facts
| NCT number | NCT00151320 |
|---|---|
| Title | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL |
| Official title | Phase I/II Trial of VELCADE+ CHOP-Rituximab in Patients With Previously Untreated Diffuse Large B Cell or Mantle Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Weill Medical College of Cornell University, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Bortezomib, CHOP, Rituximab |
| Enrollment | 76 |
| Start date | Jan 1, 2004 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 24, 2013 |
| First posted | Sep 8, 2005 |
| Last update posted | Jun 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: